West Pharmaceutical Services Inc (WST)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $29.01B
Last updated: Nov 17, 2026 at 11:06 AM ET
West Pharmaceutical Services Inc (WST) Stock Forecast
Analysts expect West Pharmaceutical Services (WST) to earn $9.46 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.42B. Of 16 analysts, 15 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 16 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 18.8% |
| Buy | 12 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 6.3% |
- Consensus
- Buy
- Total analysts
- 16
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 9.8% and revenue estimates rise 5.8%.
- Fiscal year ending Dec 31, 2026
- $9.46
- EPS consensus, revenue $3.42B
- Fiscal year ending Dec 31, 2027
- $10.39
- EPS consensus, revenue $3.62B
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $9.46 | $9.40 to $9.63 | 16 | $3.42B | $3.41B to $3.45B | 15 |
| Dec 31, 2027 | $10.39 | $9.97 to $11.08 | 16 | $3.62B | $3.51B to $3.73B | 15 |
Quarterly Estimates
The EPS consensus rises from $2.31 for the quarter ending Dec 31, 2026 to $2.35 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.31 | $2.19 to $2.44 | 13 | $833.44M | $804.58M to $870.45M | 14 |
| Mar 31, 2027 | $2.35 | $2.31 to $2.40 | 6 | $859.21M | $834.90M to $895.93M | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 28 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 16 | 0 |
| Fiscal year ending Dec 31, 2027 | 12 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 5.6% from $8.96.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $9.46 | $8.96 | $8.96 | $8.96 | $8.96 | +5.6% |
| Fiscal year ending Dec 31, 2027 | $10.39 | $9.98 | $9.98 | $9.96 | $9.96 | +4.3% |
| Quarter ending Mar 31, 2027 | $2.35 | $2.28 | $2.30 | $2.29 | $2.29 | +2.4% |
Frequently Asked Questions About WST
What is the WST stock forecast?
Consensus analyst estimates put West Pharmaceutical Services's EPS at $9.46 for the fiscal year ending Dec 31, 2026, on revenue of $3.42B. The consensus rating from 16 analysts is Buy.
How do analysts rate WST stock?
Of 16 analysts covering West Pharmaceutical Services, 3 rate it Strong Buy, 12 Buy, 0 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from WST next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $9.46, with estimates from $9.40 to $9.63 from 16 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $10.39, with estimates from $9.97 to $11.08 from 16 analysts.
What revenue do analysts expect from West Pharmaceutical Services next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.42B, with estimates from $3.41B to $3.45B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.62B, with estimates from $3.51B to $3.73B.
How many analysts cover WST?
16 analysts rate West Pharmaceutical Services stock, and 16 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
WST pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors